Table 1.

Summary of combination treatment significant interactions

PNA	24-h growth		24-h cell viability
	Ertapenem	Meropenem	Ertapenem	Meropenem
α-ampC 10 µM	0.76 ± 0.11	−0.06 ± 0.18	0.44 ± 0.22	−0.2 ± 0.09
α-hycA 10 µM	0.23 ± 0.06	—	0.36 ± 0.20	—
Α-dsrB 10 µM	0.85 ± 0.06	—	0.73 ± 0.20	—
Α-bolA 10 µM	0.83 ± 0.02	—	0.75 ± 0.09	—
Α-bolA 15 µM	—	0.61 ± 0.13	—	0.77 ± 0.12
Α-flhC 10 µM	—	−0.90 ± 0.02	—	−1.11 ± 0.08
Α-ygaC 10 µM	—	−0.93 ± 0.00	—	−0.90 ± 0.04

Normalized S values (Materials and Methods) are calculated relative to drug combination predictions from the Bliss Independence Model. Plus/minus values represent SEs of the S values. Bold numbers indicate P < 0.05, after adjustment for multiple hypothesis testing.